Data from the Company’s Phase 2 Trial evaluating NE3107 in Parkinson’s Disease will be presented orally during the symposium Advances in PD and LDB Diagnosis and Drug Development (ID#124). A poster presentation on the pharmacokinetic profile of NE3107 will also be given. Both the oral presentation and poster will be available virtually throughout the event.
BioVie Announces Data from Phase 2 Parkin... - Cure Parkinson's
BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
globenewswire.com/news-release/2024/05/09/2878650/0/en/Annovis-Announces-Unblinding-of-the-Buntaneta
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease
https://finance.yahoo.com/news/neuraly-announces-topline-results-phase-110000617.html
Neuraly...
Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months
https://www.prnewswire.com/news-releases/annovis-bio-announces-completion-of-phase-iii-parkinsons-di
Recording now available for NoSilverBullet/Cure Parkinson’s presentation by Dr Simon Stott on his main PD research takeaways from 2023/24
It is also available as a Podcast on all major Podcast providers.
We will be announcing our next...
Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD
Highlights
• Oral NR increases brain NAD levels in individuals with Parkinson’s disease
• NR...
Related Posts
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE- AnnovisBio has initiated a 6-month Phase 3 study to evaluate 2 different doses Buntanetap (posiphen) in 450 participants with PD
- Does it indicate failure of another clinical trial
- Can we give CuATSM a try without waiting for the Australian trial completion (5 years from now)
